BioXcel Therapeutics Files 8-K
Ticker: BTAI · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1720893
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
BioXcel Therapeutics filed an 8-K on Aug 12, 2025, for financial updates.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event for the company.
Why It Matters
This filing is a routine disclosure for BioXcel Therapeutics, Inc., providing updates on its financial condition and operations to investors and the public.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not appear to contain any new material events or risks.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- 555 Long Wharf Drive (location) — Principal executive offices address
- New Haven, CT 06511 (location) — Principal executive offices city, state, zip
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on BioXcel Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 12, 2025.
What is the exact name of the registrant?
The exact name of the registrant is BioXcel Therapeutics, Inc.
Where are BioXcel Therapeutics, Inc.'s principal executive offices located?
BioXcel Therapeutics, Inc.'s principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
What is the company's telephone number?
The company's telephone number is (475) 238-6837.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-08-12 08:05:24
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm2523230d1_8k.htm (8-K) — 25KB
- tm2523230d1_ex99-1.htm (EX-99.1) — 80KB
- 0001104659-25-076501.txt ( ) — 279KB
- btai-20250812.xsd (EX-101.SCH) — 3KB
- btai-20250812_lab.xml (EX-101.LAB) — 33KB
- btai-20250812_pre.xml (EX-101.PRE) — 22KB
- tm2523230d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, BioXcel Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025 and providing a business update. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Ex.No. Description 99.1 Press release, dated August 12, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the InlineXBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2025 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer